The Effect of Methylphenidate Treatment on Oxidative Stress Levels in Children Diagnosed With Attention Deficit Hyperactivity Disorder (ADHD)
Key facts
- Who runs it
- Saglik Bilimleri Universitesi
- Where
- Türkiye1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 39 people enrolled
- Started
- 26 Jun 2024
- Ended
- 6 Jan 2025
- Type of study
- Observational
- Treatments tested
- This is not an interventional study. Patients who are planned to start methylphenidate treatment have been invited to participate in the study.
- Record updated
- 8 June 2025
Who can take part
- Age
- 6 years to 11 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- - A diagnosis of "Attention Deficit Hyperactivity Disorder" according to DSM-5 TR, and the initiation or planned initiation of methylphenidate treatment as part of routine care
- Being between the ages of 6 and 11
- Providing consent to participate in the study after being informed about the study
Who cannot take part
- Previous use of psychiatric medication
- Use of regular medication
- - Presence of a psychiatric disorder diagnosis other than "Attention Deficit Hyperactivity Disorder."
- The diagnosis of "Attention Deficit Hyperactivity Disorder" has been made, but methylphenidate treatment has not been planned
- Presence of organic brain damage, mental retardation, autism spectrum disorder, neurological diseases, or any physical illness affecting neurocognitive functions
- A history of alcohol and/or psychoactive substance use
- Presence of ongoing active infection, allergic diseases, or chronic illness
- Presence of a chronic illness
- Being under the age of 6 or over the age of 11
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The aim of this study is to investigate the effect of methylphenidate treatment on oxidative stress by measuring the levels of Total Oxidant Status (TOS), Total Antioxidant Status (TAS), Oxidative Stress Index (OSI=TOS/TAS), Malondialdehyde (MDA), Oxidized LDL (Ox-LDL), and Superoxide Dismutase (SOD) in serum samples of patients diagnosed with Attention Deficit Hyperactivity Disorder (ADHD) who have either started or are planned to start methylphenidate treatment. The measurements will be taken at baseline (0 months, before treatment initiation) and at the 3rd month (after treatment has begun) to assess the effect of methylphenidate on oxidative stress. Patients who were already planned to begin methylphenidate treatment will be invited to participate in this study. Since this is not an interventional study, no additional treatments will be administered or altered beyond the treatment the patient is already required to receive.
The group in the trial
- Patient group
Patient group with attention deficit and hyperactivity disorder. The group planned to start methylphenidate treatment independent of the study
Treatment: This is not an interventional study. Patients who are planned to start methylphenidate treatment have been invited to participate in the study.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 8 June 2025